Publication Name	World Journal of Clinical Oncology
Manuscript ID	76757
Country	China

Received	2022-03-29 12:28
Peer-Review Started	2022-03-29 12:31
To Make the First Decision
Return for Revision	2022-05-31 01:27
Revised	2022-06-15 02:05
Second Decision	2022-07-22 07:43
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-07-25 03:06
Articles in Press	2022-07-25 03:06
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-07-14 02:19
Typeset the Manuscript	2022-08-17 09:34
Publish the Manuscript Online	2022-08-23 09:54

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Field of Vision
Article Title	Potential of mRNA vaccines to become versatile cancer vaccines
Manuscript Source	Invited Manuscript
All Author List	Shiu-Ying Tsao
ORCID	Author(s) ORCID Number Shiu-Ying Tsao http://orcid.org/0000-0002-5787-9664
Funding Agency and Grant Number
Corresponding Author	Shiu-Ying Tsao, MBBS, Academic Research, Department of Oncology, Hong Kong SAR Oncology Centre, 12/F McDonald's Building, 46-54 Yee Wo Street, Hong Kong SAR 999077, China. sy_tsao@yahoo.com
Key Words	Cancer vaccine; Cyclophosphamide; Metformin; Metronomic chemotherapy; mRNA vaccine; Myocarditis; Tumor microenvironment
Core Tip	Although vaccines are effective for pathogen prevention and cancers, hitherto, oncology vaccines have not yet made a very significant clinical impact. Currently, as mRNA vaccines already have a proven safety profile, it is highly appropriate to further develop the decades-old mRNA technology for oncology. Compared to other approved cancer vaccines, oncology mRNA vaccines may be more versatile, pragmatic, affordable and effective. To combat the notoriously resistant tumor microenvironment, the probable mutual enhancement effects with, e.g., metronomic chemotherapy should be fully explored, especially as no significant added toxicity is anticipated. Clearly, undertaking much more research work (especially clinical) is mandatory.
Publish Date	2022-08-23 09:54
Citation	Tsao SY. Potential of mRNA vaccines to become versatile cancer vaccines. World J Clin Oncol 2022; 28(32): 4475-4492
URL	https://www.wjgnet.com/2218-4333/full/v13/i8/663.htm
DOI	https://dx.doi.org/10.5306/wjco.v13.i8.663

Full Article (PDF)	WJCO-13-663.pdf
Full Article (Word)	WJCO-13-663.docx
Manuscript File	76757_Auto_Edited-LLW-WangTQ-LS.docx
Answering Reviewers	76757-Answering reviewers.pdf
Audio Core Tip	76757-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	76757-Conflict-of-interest statement.pdf
Copyright License Agreement	76757-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	76757-Language certificate.pdf
Peer-review Report	76757-Peer-review(s).pdf
Scientific Misconduct Check	76757-Bing-Wang LL-2.png
Scientific Editor Work List	76757-Scientific editor work list.pdf